[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640599":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":37,"locations":43,"responsibleParty":58,"collaborators":11,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":81,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (polidocanol 1% group): Patients will receive polidocanol 1 %, a maximum of one milliliter o","ACTIVE_COMPARATOR",null,[13],"Drug: Group 1 (polidocanol 1% group):",{"label":15,"type":10,"description":11,"interventionNames":16},"Group 2 (Triamcinolone acetonide group): Triamcinolone acetonide will be intralesionally injected",[17],"Drug: Group 2 (Triamcinolone acetonide group):",{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3 ( combined Triamcinolone acetonide and polidocanol 1% group)","The lesion will be injected 0.1ml\u002F cm2 Triamcinolone acetonide and 0.1 ml\u002Fcm2 polidocanol 1 %, with maximum 1ml Triamcinolone acetonide and 1 ml polidocanol 1 %.",[22],"Drug: Group 3 (combined Triamcinolone acetonide and polidocanol 1% group):",[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Group 1 (polidocanol 1% group):","Patients will receive polidocanol 1 %, a maximum of one milliliter of polidocanol 1% will be injected in each lesion using an insulin syringe with a 24-gauge needle.3- The active substance will be injected intralesionally every 2 weeks for maximum 6 sessions or complete flattening of the lesion.",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Group 2 (Triamcinolone acetonide group):","Triamcinolone acetonide will be intralesionally injected at concentration of 20 mg\u002Fml, a maximum of one-milliliter triamcinolone will be injected in the lesion.\n\n3- The active substance will be injected intralesionally every 2 weeks for maximum 6 sessions or complete flattening of the lesion.",[15],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"Group 3 (combined Triamcinolone acetonide and polidocanol 1% group):","The lesion will be injected 0.1ml\u002F cm2 Triamcinolone acetonide and 0.1 ml\u002Fcm2 polidocanol 1 %, with maximum 1ml Triamcinolone acetonide and 1 ml polidocanol 1 %.3- The active substance will be injected intralesionally every 2 weeks for maximum 6 sessions or complete flattening of the lesion.",[19],[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"raghda mohamed hassan Raghda Mohamed Hassan, assistant lecturer","CONTACT","01009683988","raghdahmohammad@med.sohag.edu.eg",[44],{"facility":5,"status":11,"city":45,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Sohag","Egypt","EG",{"type":49,"coordinates":50},"Point",[51,52],31.69478,26.55695,{"lat":52,"lon":51},[55],{"name":56,"role":40,"phone":41,"phoneExt":11,"email":57},"Raghda Mohammed Hassan Raghda Mohammed Hassan, assistant lecturer","raghdhmohammad@med.sohag.edu.eg",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Raghda Mohamed Hassan","assistent lecturer","100640599","polidocanol-1-and-steroid-in-keloids-and-hypertrophic-scars-100640599",false,"NCT07606391","Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars","Efficacy and Safety of Intralesional Injection of Polidocanol 1% in Treatment of Keloids and Hypertrophic Scars","Inclusion Criteria:\n\n\\- Patients older than 16 years of both sex with keloids and\u002For hypertrophic scars ≤ year.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation.\n2. Skin lesions, infection in the injection area.\n3. Patients with systemic disease (diabetes mellitus, heart disease, cancer, mental illness).\n4. Allergy to substances used.\n5. Patients received treatment in previous 4 weeks.\n6. Current anticoagulant therapy.\n7. Active thromboembolic disease, use of oral contraceptives or other drugs affecting coagulation cascade.\n8. History of venous or arterial thromboembolism.\n9. Severe renal dysfunction.","ALL","16 Years","60 Years",{"count":73,"type":74},90,"ESTIMATED","INTERVENTIONAL",[77],"NA","we will inject intralesional polidocanol 1% in keloids and hypertrophic scars to decrease vascularity and decrease size of lesion compared to intralesional steroid as standard treatment line",[80],"Keloid and Hypertrophic Scars","NOT_YET_RECRUITING","2026-05-18",{"date":84,"type":85},"2026-05-26","ACTUAL",{"date":87,"type":74},"2026-08-01",{"date":89,"type":74},"2027-08-01",{"name":5,"class":6},1]